Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of DWJ1445 and DWC202506 in Healthy Adults
NCT07256600Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DWJ1445 (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area under the plasma drug concentration-time curve from time 0 to 24 hours and Maximum plasma concentration. Started Nov 2025; status: completed.
02
Drugs
DWJ1445
Beyond the preview
Go deeper on NCT07256600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07256600.